Table 1. Results of local response and survival in recent studies.

Study (year)	Local response (%)	Survival (%)	Comment	Ref.
Varela et al. (2007)	Response: 66 PR: 44.4† SD: 25.9† CR: 25.9‡	At 12 months: 92.5 At 24 months: 88.9	On intention-to-treat	[4]
Poon et al. (2007)	CR: 6.7 PR: 63.3	At 12 months: 92.5 At 24 months: 88.9	Prospective study Results at 1 month	[5]
Malagari et al. (2008)	CR: 12.2 PR: 75.6 PD: 6.8 SD: 12.2	NA	At 9 months after three scheduled sessions Prospective study	[15]
Malagari et al. (2008)	CR: 16.1 OR: 72	At 18 months: 94.1 At 30 months: 88.2	After three scheduled sessions Prospective study	[16]
Kettenbach et al. (2008)	CR: 27 PR: 13 PD: 40 SD: 3	At 6 months: 93	Prospective study	[17]
Sacco et al. (2011)	CR: 51.5§ PR: 48.5§ PD: 17.9	At 24 months estimated: 86.8	Prospective–randomized study	[18]
Sycha et al. (2012)	OR: 89%	NA	NA	[20]
Dhanasekaran et al. (2010)	NA	At 6 months: 71 At 12 months: 58 At 24 months: 48 Median survival 610 days§	Retrograde study	[22]
Lammer et al. (2010)	CR: 27§ OR: 52§ DC: 63§	NA	Prospective–randomized study	[24]
Malagari et al. (2012)	CR: 22.5–23.5¶ PR: 46.5–49¶ PD: 8.4–4.9¶ SD: 22.5¶	At 12 months: 93.6 At 24 months: 83.8 At 3 years: 62.0 At 4 years: 41.0 At 5 years: 22.5 Mean overall survival: 43.8 months	Prospective study After three scheduled sessions and then on demand	[27]
Burrel et al. (2012)	NA	Median survival after censoring at the time of transplant/sorafenib was 47.7 months	Prospective study	[28]

^†Response Evaluation Criteria In Solid Tumors criteria.

^‡WHO-modified criteria.

^§In the DC Bead™ arm.

^¶Range for Child–Pugh A and Child–Pugh B cirrhosis.

CR: Complete response; DC: Disease control (complete response plus partial response plus stable disease); NA: Not applicable; OR: Objective response (complete response plus partial response); PD: Progressive disease; PR: Partial response; SD: Stable disease.